ISRCTN56916002 https://doi.org/10.1186/ISRCTN56916002

Does the underlying haemodynamic abnormality determine response to antihypertensive therapy?

Submission date 12/05/2010	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 12/05/2010	**Overall study status** Completed	
Last Edited 04/08/2016	**Condition category** Circulatory System	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mrs Michaela Watts

Contact details
Addenbrookes Hospital
Hills Road
Cambridge
United Kingdom
CB2 2QQ

Additional identifiers

Clinical Trials Information System (CTIS)
2006-006981-40

Protocol serial number
5293

Study information

Scientific Title

Does the underlying haemodynamic abnormality determine response to antihypertensive therapy?

Acronym
Rotation Study

Study objectives
The purpose of the study/trial is to find out the relation of haemodynamic abnormalities in 60 patients with hypertension and their responses to different classes of antihypertensive agents.

Ethics approval required
Old ethics approval format

Ethics approval(s)
MREC approved, ref: 07/Q0108/33

Study design
Single-centre randomised interventional treatment trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Topic: Cardiovascular; Subtopic: Cardiovascular (all Subtopics); Disease: Cardiovascular

Interventions
Patients will be enrolled and the following data is collected:
1. History
2. Physical examination
3. Height
4. Weight
5. Blood tests
6. Electrocardiogram (ECG)
7. Haemodynamic measurements

Administration of medications will be in a double-blind randomised placebo controlled cross-over methodology: doxazosin 1 - 4 mg, bisoprolol 2.5 - 5 mg, candesartan 8 - 16 mg, isosorbide mononitrate M/R 25 - 50 mg

There will be 42 days per treatment phase and 36 weeks in total.

Intervention Type
Drug

Phase
Not Applicable

Drug/device/biological/vaccine name(s)

Doxazosin, bisoprolol, candesartan, isosorbide mononitrate

Primary outcome(s)
Difference in BP change according to pre-specified group analysis.

Key secondary outcome(s))
1. Change in haemodynamic parameters achieved by different study medication
2. Number of patients reaching target BP

Completion date
01/08/2009

Eligibility

Key inclusion criteria
Hypertensive patients

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Sex
All

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/06/2007

Date of final enrolment
01/08/2009

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Addenbrookes Hospital
Cambridge

United Kingdom
CB2 2QQ

Sponsor information

Organisation
Cambridge University Hospitals NHS Foundation Trust (UK)

ROR
https://ror.org/04v54gj93

Funder(s)

Funder type
Charity

Funder Name
British Heart Foundation (BHF) (UK)

Alternative Name(s)
the_bhf, The British Heart Foundation, BHF

Funding Body Type
Private sector organisation

Funding Body Subtype
Trusts, charities, foundations (both public and private)

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
	results				

Results article		01/01/2014		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes